Supplementary Table. Common adverse events in primary studies[a]

	START [20] (N=12), n (%)	STR1VE-US [21] (N=22), n (%)	STR1VE-EU [22] (N=33), n (%)
All adverse events	12 (100)	22 (100)	32 (97)
Pyrexia	6 (50)	12 (55)	22 (67)
Upper respiratory tract infection	10 (83)	11 (50)	11 (33)
Vomiting	8 (67)	4 (18)	8 (24)
Constipation	7 (58)	9 (41)	7 (21)
Nasal congestion	6 (50)	3 (14)	4 (12)
Increased ALT	—	5 (23)	9 (27)
Increase AST	1 (8)	6 (27)	8 (24)
Increased aminotransferase concentration	3 (25)	—	—
Drug-related adverse events	3 (25)	12 (55)	24 (73)

Pyrexia	—	—	4 (12)
Constipation	—	—	1 (3)
Increased ALT	—	5 (23)	7 (21)
Increase AST	1 (8)	6 (27)	6 (18)
Serious adverse events	10 (83)	10 (45)	19 (58)
Pyrexia	—	—	4 (12)
Upper respiratory tract infection	3 (25)	1 (5)	3 (9)
Nasopharyngitis	—	—	1 (3)
Increased ALT	—	1 (5)	1 (3)
Increase AST	—	1 (5)	1 (3)
Serious and drug-related adverse events	3 (25)	3 (14)	6 (18)
Pyrexia	—	—	2 (6)
Increased ALT	—	1 (5)	1 (3)
Increased AST	—	1 (5)	1 (3)

ALT, alanine aminotransferase; AST, aspartate aminotransferase.

[a]Based on the safety population set in each study.